Neurofibromatosis type 1: Difference between revisions
No edit summary |
MoisesRomo (talk | contribs) |
||
Line 17: | Line 17: | ||
==[[Neurofibromatosis type 1 causes|Causes]]== | ==[[Neurofibromatosis type 1 causes|Causes]]== | ||
==[[Neurofibromatosis type 1 differential diagnosis|Differentiating | ==[[Neurofibromatosis type 1 differential diagnosis|Differentiating neurofibromatosis type 1 from other Diseases]]== | ||
==[[Neurofibromatosis type 1 epidemiology and demographics|Epidemiology and Demographics]]== | ==[[Neurofibromatosis type 1 epidemiology and demographics|Epidemiology and Demographics]]== |
Revision as of 23:47, 17 June 2020
Neurofibromatosis type 1 Microchapters |
Differentiating Neurofibromatosis type 1 from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Neurofibromatosis type 1 On the Web |
American Roentgen Ray Society Images of Neurofibromatosis type 1 |
Risk calculators and risk factors for Neurofibromatosis type 1 |
For patient information, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Synonyms and keywords:
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating neurofibromatosis type 1 from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic study of choice | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X-Ray Findings | Echocardiography and Ultrasound | CT-Scan Findings | MRI Findings | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Interventions | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies